8-K: NeoGenomics Reports Strong 2025 Revenue, Announces CFO Transition

NeoGenomics announced preliminary unaudited fourth quarter and full-year 2025 revenue growth and a planned Chief Financial Officer succession.

Summary

• Preliminary unaudited fourth quarter 2025 revenue is expected to be approximately $190 million, representing an 11% year-over-year growth.
• Preliminary unaudited full-year 2025 revenue is expected to be approximately $727 million, representing a 10% year-over-year growth.
• Chief Financial Officer Jeff Sherman is retiring and will transition from his role to Executive Vice President on March 2, 2026, with his retirement effective April 14, 2026.
• Abhishek Jain joined the company as Executive Vice President on January 12, 2026, and will assume the role of Chief Financial Officer on March 2, 2026.
• Mr. Sherman will remain with the company as a special advisor through April 2028 to ensure a smooth transition.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary revenue growth and a well-managed CFO transition with an experienced successor, indicating positive operational and strategic momentum. The only cautionary note is the preliminary nature of the financials, which is standard.

Positives

• Strong preliminary double-digit revenue growth of 11% for Q4 2025 and 10% for full-year 2025, indicating robust business performance.
• Appointment of Abhishek Jain, an experienced life sciences finance veteran with a proven track record, as the incoming CFO.
• A well-structured CFO succession plan that includes a transition period and the outgoing CFO serving as a special advisor, ensuring continuity.
• Commitment to being a leading cancer testing partner in the community setting, which accounts for approximately 80% of cancer care delivery.
• Possession of one of the broadest oncology test menus in the industry, including innovations in therapy selection and recurrence monitoring.

Risks

• The estimated revenues are preliminary, unaudited, and based on management estimates, and are subject to change, potentially materially, as the company completes its year-end close procedures and independent auditors conduct their review.
• Risks related to the company's ability to successfully identify and implement appropriate financial and operational initiatives.
• Challenges in executing strategic priorities and managing the company's growth effectively.
• Risks associated with assembling and maintaining an effective executive management team.
• General business risks and uncertainties as identified in the company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other SEC filings.

Future Outlook

The company is well-positioned to continue its trajectory of double-digit revenue growth, scale its organization, and pursue multi-billion-dollar addressable markets in advanced cancer testing. Management aims to strengthen financial discipline, enhance operational efficiency, and support long-term value creation for shareholders while advancing its mission to improve patient care, particularly by bringing innovations in therapy selection and MRD to the community channel.

Management Comments

• "Our preliminary fourth quarter revenue reflects our ongoing commitment to being the cancer testing partner of choice to pathologists and oncologists in the community setting, where approximately 80% of cancer care is delivered today." Tony Zook, CEO.
• "With one of the broadest oncology test menus in the industry, including the latest innovations in therapy selection and recurrence monitoring, I believe we are very well positioned to continue on our trajectory of double-digit revenue growth while helping improve outcomes for cancer patients across the U.S." Tony Zook, CEO.
• "Abhishek brings a proven track record of successfully guiding life sciences companies through periods of rapid growth and transformation, and I look forward to his financial leadership as we continue to scale our organization and pursue multi-billion-dollar addressable markets in advanced cancer testing." Tony Zook, CEO.
• "I am honored to join the NeoGenomics team at this pivotal time in the company’s evolution. NeoGenomics has built a strong foundation in precision oncology diagnostics, and I look forward to working with the leadership team to further strengthen financial discipline, enhance operational efficiency, and support long-term value creation for shareholders while advancing our mission to improve patient care." Abhishek Jain, incoming CFO.
• "It has been an honor and privilege to work alongside the talented team at NeoGenomics and position the company for long-term sustainable, profitable growth. I have every confidence in the company's ability to bring the latest innovations in therapy election and MRD to oncologists and pathologists in the community channel, where these advancements have historically lagged NCI designated cancer centers." Jeff Sherman, outgoing CFO.

Industry Context

NeoGenomics operates in the rapidly evolving precision oncology diagnostics market, a sector driven by advancements in cancer genetics testing and the increasing demand for personalized medicine. The company's focus on the community setting for cancer care, where a significant portion of patients are treated, positions it to capitalize on broader trends towards decentralized healthcare and improved access to advanced diagnostics outside of major academic centers. The emphasis on a broad test menu and innovations like therapy selection and recurrence monitoring aligns with industry efforts to enhance diagnostic accuracy and treatment efficacy.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact from strong preliminary revenue growth and a well-managed CFO transition with an experienced successor, potentially leading to increased long-term value creation.
• Employees: Continuity in leadership and strategic direction, potentially fostering stability and growth opportunities within the company.
• Customers (Pathologists and Oncologists): Continued commitment to being a partner of choice, offering a broad oncology test menu and latest innovations, which could improve patient care.
• Creditors/Investors: Preliminary financial results indicate healthy growth, which could enhance confidence in the company's financial stability and future prospects.

Next Steps

• Complete customary year-end close procedures for the fiscal year ended December 31, 2025.
• Report full fourth-quarter and full-year 2025 financial results during the February 2026 earnings call.
• Abhishek Jain will assume the role of Chief Financial Officer on March 2, 2026.
• Jeffrey S. Sherman will serve as Executive Vice President until April 14, 2026, and then as a special advisor through April 2028.
• Execute an employment agreement and standard indemnification agreement for Abhishek Jain.

Key Dates

Recommendation

The company reported strong preliminary double-digit revenue growth for both Q4 and the full year 2025, indicating robust operational performance. The CFO transition is well-managed with an experienced successor, Abhishek Jain, who has a proven track record in the life sciences industry. This leadership change, coupled with the positive financial outlook and strategic focus on expanding advanced cancer testing in community settings, suggests continued positive momentum and potential for long-term value creation. While the results are preliminary, the consistent growth figures are a strong indicator.

Keywords

NeoGenomics, NEO, Oncology Diagnostics, Cancer Testing, Revenue Growth, CFO Transition, Financial Results, Precision Medicine, Abhishek Jain, Jeff Sherman, SEC Filing